---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-004080"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:39:00.670991+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q4 net revenue $23.4M, FY loss $181M; FY22 LUPKYNIS guidance $115-135M

## Summary
- Q4 2021 net revenue $23.4M (60% increase from Q3); full year net revenue $45.6M.
- Net loss Q4 $33.3M ($0.25/share) vs $8.1M ($0.06) in Q4 2020; full year $181M ($1.40/share).
- FY 2022 LUPKYNIS net revenue guidance $115-135M, representing 150-200% YoY growth.
- Cash, equivalents & investments $466.1M at Dec 31, 2021; raised $196.7M net via ATM at avg $19.91.
- AURORA 2 continuation study shows sustained efficacy; EMA MAA on track for CHMP opinion H2 2022.

## SEC filing metadata
- accession: 0001628280-22-004080
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828022004080/0001628280-22-004080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828022004080/auph-20220228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-004080
- JSON: https://secwatch.observer/filing/0001628280-22-004080.json
- Plain text: https://secwatch.observer/filing/0001628280-22-004080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.